Biotech sues AstraZeneca and Cellectis over mRNA patents

Complaint alleges the pair used Massachusetts company’s patented mRNA TALEN gene-editing technology without permission in multi-billion-dollar cancer therapy deals.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

US university treats cancer patients with CRISPR

17 April 2019 The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.

Biotechnology

AstraZeneca to launch CRISPR-based cancer research centre

11 December 2018 Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.

Americas

Cellectis to license recently-granted CRISPR patents

14 February 2018 French cell therapy company Cellectis has announced plans to make two CRISPR patents, which were recently granted by the US Patent and Trademark Office, available for licensing.

More features

Trump threatens 100% tariff hike on pharma imports into the US

Budgets, CRISPR, and keeping pace with tech: top challenges for Europe’s patent pros

EU court delivers verdict on Biogen’s market exclusivity for MS drug

Mewburn expands AI and medtech expertise with London hire

AbbVie faces secrets lawsuit over $2.1bn Capstan deal

All eyes on Squires: What IP experts want from the new USPTO director

Crafting claim strategies in animal and human therapeutics

MSD scores second win in patent fight over Keytruda

Biotech sues AstraZeneca and Cellectis over mRNA patents

More on this story

Editor's picks

Editor's picks

More features